AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28533290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 26120594 — intervention group
Group type: EXPERIMENTAL
Intervention: Spear and Shield intervention
Number of subjects: 800
Study 26120594 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study 22795088 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP compliant users (EE2 and LNG)
Number of subjects: 0
Study 21163939 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 μg twice daily for 1 year
Number of subjects: 202
Study 21163939 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 202
Study 21163939 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 202
Study 21163939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 19625946 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/day rhGH for 40 weeks
Number of subjects: 46
Study 19625946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16539642 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 23
Study 16539642 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (Control)
Number of subjects: 23
Study 12589449 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions in terms of fingers/hands for responding in visual and auditory Simon tasks
Number of subjects: 0
Study 12589449 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli with finger/hand instructions in Experiment 4
Number of subjects: 0
Study 11097665 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 10 mL saline
Number of subjects: 66
Study 11097665 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 10 mL 0.25% bupivacaine
Number of subjects: 66
Study 11097665 — intervention group
Group type: COMPARATOR
Intervention: 8 mg of 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 66
Study 11097665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 66
Study 9351153 — intervention group
Group type: EXPERIMENTAL
Intervention: Random allocation of treatment
Number of subjects: 0
Study 8176999 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily
Number of subjects: 71
Study 8176999 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 71
Study 2412071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin, 40 mg b.i.d. for 8 weeks
Number of subjects: 23
Study 2412071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30517252 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,600 mg of oral magnesium hydroxide through nasogastric (NG) tube prior to surgery
Number of subjects: 82
Study 30517252 — intervention group
Group type: COMPARATOR
Intervention: 2 g of magnesium sulfate during the induction of anesthesia
Number of subjects: 82
Study 26423618 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mg pegteograstim
Number of subjects: 117
Study 26423618 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 mg pegteograstim
Number of subjects: 117
Study 26423618 — intervention group
Group type: COMPARATOR
Intervention: 6.0 mg pegfilgrastim
Number of subjects: 117
Study 24560332 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 284
Study 24560332 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/Vinorelbine (AUC5 and 25mg/m2 on days 1 and 8 every three weeks)
Number of subjects: 284
Study 24560332 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 284
Study 24560332 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/Vinorelbine
Number of subjects: 284
Study 22674719 — intervention group
Group type: COMPARATOR
Intervention: sulfaphenazole (cytochrome P450 inhibitor)
Number of subjects: 20
Study 22674719 — intervention group
Group type: COMPARATOR
Intervention: tetraethylammonium (TEA, KCa channel inhibitor)
Number of subjects: 20
Study 22674719 — intervention group
Group type: COMPARATOR
Intervention: l‐NAME (NO synthase inhibitor)
Number of subjects: 20
Study 22674719 — intervention group
Group type: COMPARATOR
Intervention: sulfaphenazole + l‐NAME
Number of subjects: 20
Study 22674719 — intervention group
Group type: COMPARATOR
Intervention: l‐NAME + TEA
Number of subjects: 20
Study 22674719 — intervention group
Group type: COMPARATOR
Intervention: TEA + l‐NAME
Number of subjects: 20
Study 20570110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200-1000 mg) plus Celecoxib (400 mg)
Number of subjects: 49
Study 20570110 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride (200-1000 mg) plus Placebo
Number of subjects: 49
Study 17562798 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Number of subjects: 0
Study 16055641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 0
Study 16055641 — intervention group
Group type: COMPARATOR
Intervention: Uncertainty Salience (Control)
Number of subjects: 0
Study 12205570 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose salmeterol (100 mcg, BID)
Number of subjects: 44
Study 12205570 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (2.5 mg, BID)
Number of subjects: 44
Study 10433674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver-coated dressing
Number of subjects: 0
Study 10433674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mafenide acetate
Number of subjects: 0
Study 10433674 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 0
Study 10433674 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 0
Study 8543356 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-NaCl method
Number of subjects: 125
Study 8543356 — intervention group
Group type: COMPARATOR
Intervention: NaOH method
Number of subjects: 125
Study 2358610 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (270 mg/day)
Number of subjects: 18
Study 2358610 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 18
Study 2358610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7178 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine 10 mg t.i.d. (first week) and 20 mg t.i.d. (second week)
Number of subjects: 20
Study 7178 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam 6 mg t.i.d. during two weeks
Number of subjects: 20
Study 7178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam combined with alcohol
Number of subjects: 20
Study 7178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7178 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (combined with bromazepam)
Number of subjects: 20
Study 7178 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (combined with thioridazine)
Number of subjects: 20
Study 30584116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid tape applied for 2 weeks
Number of subjects: 37
Study 30584116 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 37
Study 29097357 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX‐R (gamified online cognitive behavior therapy intervention)
Number of subjects: 540
Study 29097357 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 540
Study 25322475 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 11
Study 25322475 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise
Number of subjects: 11
Study 23013104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture
Number of subjects: 154
Study 23013104 — intervention group
Group type: EXPERIMENTAL
Intervention: Website
Number of subjects: 154
Study 23013104 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-based tutorial
Number of subjects: 154
Study 23013104 — intervention group
Group type: EXPERIMENTAL
Intervention: Handout
Number of subjects: 154
Study 22164809 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 81
Study 22164809 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga as exercise
Number of subjects: 81
Study 22164809 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study 19639376 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% supplemental intraoperative oxygen
Number of subjects: 304
Study 19639376 — intervention group
Group type: COMPARATOR
Intervention: Routine 30% oxygen (control)
Number of subjects: 304
Study 16424411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil diet (3.2 g eicosapentaenoic acid and 2.0 g docohexaenoic acid)
Number of subjects: 16
Study 16424411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil diet
Number of subjects: 16
Study 16424411 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 16
Study 16424411 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 16
Study 15227625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alanyl-glutamine
Number of subjects: 0
Study 15227625 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0
Study 15227625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine
Number of subjects: 0
Study 15227625 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous glycine)
Number of subjects: 0
Study 11063148 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg/h)
Number of subjects: 9
Study 11063148 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 9060533 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (30 mg/d for 2 weeks followed by 10 weeks of no drug, repeated for 8 cycles)
Number of subjects: 53
Study 9060533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8339412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 1200 mg bamiphylline
Number of subjects: 18
Study 8339412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of bamiphylline (5 mg/kg in 15 minutes)
Number of subjects: 18
Study 3333290 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 253
Study 3333290 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 253
Study 3333290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 31477194 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 100
Study 30158004 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure supplemented with phone‐based in‐depth messaging
Number of subjects: 1000
Study 30158004 — intervention group
Group type: COMPARATOR
Intervention: Brochure containing information on risks, benefits, and costs associated with lung cancer screening
Number of subjects: 1000
Study 27391493 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded tapered implants in postextraction sockets
Number of subjects: 39
Study 27391493 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded tapered implants in healed sites
Number of subjects: 39
Study 27391493 — intervention group
Group type: COMPARATOR
Intervention: Both groups (postextraction sockets and healed sites)
Number of subjects: 39
Study 25079049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonothrombolysis (transcranial Doppler monitoring plus intravenous tissue plasminogen activator)
Number of subjects: 85
Study 25079049 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator alone
Number of subjects: 85
Study 23156967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy with energy dose of 52.5 J/cm2 (G-I)
Number of subjects: 45
Study 23156967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy with energy dose of 105.0 J/cm2 (G-II)
Number of subjects: 45
Study 23156967 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (0 J/cm2) (G-III)
Number of subjects: 45
Study 21171265 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (4 mg/d)
Number of subjects: 64
Study 21171265 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg/d) plus Doxazosin (4 mg/d)
Number of subjects: 64
Study 18930104 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 52
Study 18930104 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 52
Study 18930104 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 52
Study 15970833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin given at skin incision (group A)
Number of subjects: 303
Study 15970833 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin given at cord clamping (group B)
Number of subjects: 303
Study 12907898 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 101
Study 12907898 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 101
Study 10486696 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day for 4 weeks
Number of subjects: 20
Study 10486696 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study 8759578 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac 60 mg
Number of subjects: 154
Study 8759578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IV ketorolac 60 mg and meperidine 50 mg
Number of subjects: 154
Study 8759578 — intervention group
Group type: COMPARATOR
Intervention: IV meperidine 50 mg
Number of subjects: 154
Study 1747501 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once a day)
Number of subjects: 43
Study 1747501 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg once a day)
Number of subjects: 43
Study 7052040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 37
Study 7052040 — intervention group
Group type: COMPARATOR
Intervention: Combined cyclophosphamide and cis-diamminedichloroplatinum (cis DDP)
Number of subjects: 37
Study 31792640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 0.5 mg
Number of subjects: 200
Study 31792640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg
Number of subjects: 200
Study 31792640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 2 mg
Number of subjects: 200
Study 31792640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad 4 mg
Number of subjects: 200
Study 31792640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30806926 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw returning
Number of subjects: 0
Study 30806926 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding of forage
Number of subjects: 0
Study 30806926 — intervention group
Group type: COMPARATOR
Intervention: RC treatment
Number of subjects: 0
Study 30806926 — intervention group
Group type: COMPARATOR
Intervention: RC model
Number of subjects: 0
Study 29122126 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct reduction via a posterolateral approach and posteroanterior (PA) fixation
Number of subjects: 48
Study 29122126 — intervention group
Group type: COMPARATOR
Intervention: Indirect reduction and anteroposterior (AP) fixation
Number of subjects: 48
Study 25881835 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbo forceps polypectomy
Number of subjects: 212
Study 25881835 — intervention group
Group type: COMPARATOR
Intervention: Standard forceps polypectomy
Number of subjects: 212
Study 23812093 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment program (9 sessions)
Number of subjects: 70
Study 21558576 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) solution 140 mg/kg
Number of subjects: 0
Study 21558576 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) 140 mg/kg
Number of subjects: 0
Study 21558576 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) capsules (low doses)
Number of subjects: 0
Study 19655666 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD1
Number of subjects: 246
Study 19655666 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD2
Number of subjects: 246
Study 19655666 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation and association tests
Number of subjects: 246
Study 19655666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronbach's Alpha
Number of subjects: 246
Study 19655666 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard criterion vs scale
Number of subjects: 246
Study 16728521 — intervention group
Group type: EXPERIMENTAL
Intervention: High peak SBP group (peak SBP > 210 mmHg)
Number of subjects: 28
Study 16728521 — intervention group
Group type: COMPARATOR
Intervention: Low peak SBP group (peak SBP ≤ 210 mmHg)
Number of subjects: 28
Study 16728521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 14982543 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions for practitioners in training
Number of subjects: 24
Study 14982543 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based interventions
Number of subjects: 24
Study 14982543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of practice-based and educational interventions
Number of subjects: 24
Study 14982543 — intervention group
Group type: COMPARATOR
Intervention: Interventions (general)
Number of subjects: 24
Study 11303007 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor 2 g twice a day
Number of subjects: 59
Study 11303007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9231969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic strength back muscle training at a fitness center for the first 3 months, followed by a home training program
Number of subjects: 74
Study 9231969 — intervention group
Group type: COMPARATOR
Intervention: Home training program for the first 3 months, followed by continued home training
Number of subjects: 74
Study 8518552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine + Interferon-alpha 2a
Number of subjects: 170
Study 8518552 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 170
Study 3101790 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial spatula
Number of subjects: 17000
Study 29310613 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outcall program (n = 108)
Number of subjects: 216
Study 29310613 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n = 108)
Number of subjects: 216
Study 26447752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe Vera Gel (AV)
Number of subjects: 60
Study 26447752 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 60
Study 26280589 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 147
Study 26280589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment + Contingency Management (CBT + CM)
Number of subjects: 147
Study 23052606 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 186
Study 23052606 — intervention group
Group type: COMPARATOR
Intervention: PD patients
Number of subjects: 186
Study 21965360 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed 45 degrees at the thigh and maintained in that position for 15 minutes (group 2)
Number of subjects: 90
Study 21965360 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal tourniquet applied with the leg in a neutral position during injection (group 3)
Number of subjects: 90
Study 21965360 — intervention group
Group type: COMPARATOR
Intervention: Neutral position of the leg immediately after the patient was turned supine (group 1)
Number of subjects: 90
Study 18385595 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 18385595 — intervention group
Group type: COMPARATOR
Intervention: Control group (Morphine PCA without Naloxone)
Number of subjects: 0
Study 16826026 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) supplementation (2 g of L-carnitine per day)
Number of subjects: 10
Study 16826026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-resistance exercise (RE) feeding (8 kcal/kg body mass: 56% carbohydrate, 16% protein, 28% fat)
Number of subjects: 10
Study 16826026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 16826026 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding trials
Number of subjects: 10
Study 16826026 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) supplementation
Number of subjects: 10
Study 14520724 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 12
Study 14520724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10802363 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 Gy in 10 fractions
Number of subjects: 500
Study 10802363 — intervention group
Group type: COMPARATOR
Intervention: 21 Gy in 3 fractions
Number of subjects: 500
Study 10802363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 500
Study 8639131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 69
Study 8639131 — intervention group
Group type: COMPARATOR
Intervention: Ambi hip screw
Number of subjects: 69
Study 1483879 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL hyperbaric tetracaine
Number of subjects: 102
Study 1483879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL hyperbaric tetracaine
Number of subjects: 102
Study 1483879 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL hyperbaric tetracaine
Number of subjects: 102
Study 1483879 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg epinephrine added to anesthetic solution
Number of subjects: 102
Study 3883701 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 63
Study 3883701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30725192 — intervention group
Group type: EXPERIMENTAL
Intervention: LHB tenodesis
Number of subjects: 20